Grambart Sean T
Carle Physician Group, 1802 South Mattis Avenue, Champaign, IL 61821, USA.
Clin Podiatr Med Surg. 2015 Jan;32(1):99-107. doi: 10.1016/j.cpm.2014.09.006.
A Cochrane Review was performed to assess the effects of platelet-rich therapies for treating musculoskeletal soft tissue injuries. Selection criteria were randomized and quasirandomized controlled trials (RCTs) that compared platelet-rich therapy with either placebo, autologous whole blood, dry needling, or no platelet-rich therapy for people with acute or chronic musculoskeletal soft tissue injuries. Primary outcomes were functional status, pain, and adverse effects. The investigators found 19 studies that compared platelet-rich therapy with placebo, autologous whole blood, dry needling, or no platelet-rich therapy. Disorders included rotator cuff tears (arthroscopic repair; 6 trials); shoulder impingement syndrome surgery (1 trial); elbow epicondylitis (3 trials); anterior cruciate ligament (ACL) reconstruction (4 trials), ACL reconstruction (donor graft site application; 2 trials), patellar tendinopathy (1 trial), Achilles tendinopathy (1 trial), and acute Achilles rupture surgical repair (1 trial). They further subdivided the studies based on type of treatment, including tendinopathies in which platelet-rich therapy injections were the main treatment (5 trials), and surgical augmentation procedures in which platelet-rich therapy was applied during surgery (14 trials). The conclusion was that there is currently insufficient evidence to support the use of platelet-rich therapy for treating musculoskeletal soft tissue injuries. Researchers contemplating RCTs should consider the coverage of currently ongoing trials when assessing the need for future RCTs on specific conditions. There is a need for standardization of PRP preparation methods. At this time, the use of PRP in foot and ankle surgery as an orthobiologic does not have an absolute indication. Many of the studies are lower evidence-based from surgical techniques. Several in vitro studies have shown that growth factors promote the regeneration of bone, cartilage, and tendons. More clinical studies are needed to evaluate the use of PRP as an orthobiologic. In the author’s opinion, PRP does have a role when conservative treatment has failed and the next treatment option is an invasive surgical procedure
进行了一项Cochrane系统评价,以评估富血小板疗法治疗肌肉骨骼软组织损伤的效果。选择标准为随机和半随机对照试验(RCT),这些试验比较了富血小板疗法与安慰剂、自体全血、干针疗法或无富血小板疗法,用于治疗急性或慢性肌肉骨骼软组织损伤的患者。主要结局为功能状态、疼痛和不良反应。研究人员发现了19项将富血小板疗法与安慰剂、自体全血、干针疗法或无富血小板疗法进行比较的研究。疾病包括肩袖撕裂(关节镜修复;6项试验);肩峰撞击综合征手术(1项试验);肘外侧肌腱炎(3项试验);前交叉韧带(ACL)重建(4项试验),ACL重建(供体移植物部位应用;2项试验),髌腱病(1项试验),跟腱病(1项试验),以及急性跟腱断裂手术修复(1项试验)。他们根据治疗类型进一步细分了研究,包括以富血小板疗法注射为主要治疗手段的肌腱病(5项试验),以及在手术期间应用富血小板疗法的手术增强程序(14项试验)。结论是,目前没有足够的证据支持使用富血小板疗法治疗肌肉骨骼软组织损伤。考虑进行RCT的研究人员在评估未来针对特定情况进行RCT的必要性时,应考虑当前正在进行的试验的覆盖范围。需要对富血小板血浆(PRP)制备方法进行标准化。目前,PRP在足踝手术中作为一种组织工程生物材料的使用没有绝对指征。许多研究的手术技术证据级别较低。一些体外研究表明,生长因子可促进骨、软骨和肌腱的再生。需要更多的临床研究来评估PRP作为组织工程生物材料的应用。作者认为,当保守治疗失败且下一个治疗选择是侵入性手术时,PRP确实有作用